ADHD
About ADHD
ADHD is a neurodevelopmental condition characterized by patterns of inattention, hyperactivity, and impulsivity. In recent times, the topic has gained prominence across public health discussions, workplace accommodations, educational strategies, and digital therapeutics aimed at assessment, treatment, and support for individuals with ADHD.
Trend Decomposition
Trigger: Increased public awareness and diagnosis rates, plus growing interest in neurodiversity and mental health in schools and workplaces.
Behavior change: More people seek evaluation, pursue tailored treatment plans, and adopt organizational tools and routines; clinicians increasingly utilize digital assessment and therapeutic options.
Enabler: Advances in digital therapeutics, telemedicine, data driven assessment tools, and scalable pharmacological options enable broader access and personalized management.
Constraint removed: Stigma around seeking evaluation and the barriers to accessing specialized ADHD care are reduced by online resources and remote services.
PESTLE Analysis
Political: Public health priorities and funding for mental health services influence ADHD screening and treatment access.
Economic: Rising healthcare costs and insurance coverage patterns affect affordability of diagnosis, therapy, and medications.
Social: Increased visibility of ADHD in media and education drives demand for accommodations and support networks.
Technological: Proliferation of digital therapeutics, app based coaching, and data driven monitoring enhances management.
Legal: Regulatory oversight for digital therapeutics and ADHD medications shapes product approvals and reimbursement.
Environmental: Workplace and school environments evolve to be more ADHD aware, with accommodations embedded in policy and design.
Jobs to be done framework
What problem does this trend help solve?
Diagnosis delays, inconsistent treatment, and lack of access to personalized ADHD management.What workaround existed before?
Generalized treatment approaches, paper based assessments, and limited remote care options.What outcome matters most?
Certainty in diagnosis and effectiveness of tailored interventions delivered conveniently and affordably.Consumer Trend canvas
Basic Need: Effective and accessible ADHD management for improved daily functioning.
Drivers of Change: Greater mental health emphasis, digital health adoption, and demand for individualized care.
Emerging Consumer Needs: Real time tracking, personalized treatment plans, and stigma free access to care.
New Consumer Expectations: Higher transparency, evidence based digital tools, and seamless integration with education and work life.
Inspirations / Signals: FDA approvals of digital therapeutics for ADHD and scaling telehealth platforms.
Innovations Emerging: AI assisted assessments, digital therapeutics like EndeavorRx, and remote coaching programs.
Companies to watch
- Akili Interactive - Developer of EndeavorRx, a digital therapeutic for ADHD; active in ADHD related digital health approaches.
- Eli Lilly - Pharmaceutical company with ADHD medications and research into neurodevelopmental disorders.
- Johnson & Johnson (Janssen Pharmaceuticals) - Legacy ADHD and neuropsychiatric portfolio through Janssen; ongoing interest in ADHD treatments and related research.
- Takeda - Global pharmaceutical company involved in neuropsychiatric medicines and ADHD related therapies through legacy products.